1. Home
  2. ATXG vs GRI Comparison

ATXG vs GRI Comparison

Compare ATXG & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATXG

Addentax Group Corp.

N/A

Current Price

$4.80

Market Cap

4.1M

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$2.24

Market Cap

3.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ATXG
GRI
Founded
2014
2018
Country
China
United States
Employees
112
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
3.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ATXG
GRI
Price
$4.80
$2.24
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
69.2K
75.7K
Earning Date
02-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.18
52 Week High
$7.94
$6.70

Technical Indicators

Market Signals
Indicator
ATXG
GRI
Relative Strength Index (RSI) 51.31 40.93
Support Level $4.79 $2.15
Resistance Level $7.92 $2.23
Average True Range (ATR) 1.02 0.14
MACD -0.34 -0.03
Stochastic Oscillator 9.41 9.80

Price Performance

Historical Comparison
ATXG
GRI

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: